Beta
ManageChatDiscover
277777

Resistance of Oral Candida albicans Infection to Fluconazole and Nystatin among Healthy Persons after Treatment with Azithromycin and Hydroxychloroquine to Treat Suspected SARS-C

Article

Last updated: 05 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Antimicrobial agents

Abstract

Background: Oral candidiasis is considered the most common fungal infection in humans. Polyene or azole antifungal drugs can be used for Candida infection. In addition, Nystatin therapy is used in mild forms of oral candidiasis. However, the current literature reports conflicting results regarding azithromycin and hydroxychloroquine for COVID-19. Objective: We aim to evaluate the resistance of oral Candida albicans to fluconazole and nystatin in healthy individuals who have received therapy for suspected COVID-19 with azithromycin and hydroxychloroquine. Methodology: The current case-control study collected samples of oral candidiasis from two types of patients. The cases group (group 1) were patients with confirmed COVID-19; the control group (group 2) were healthy controls without previous COVID-19. The antifungal susceptibility was examined based on the principles of M44-A suggested by the Clinical and Laboratory Standards Institute (CLSI). Results: Thirty patients were included in the cases group. In terms of the antifungal susceptibility between the study groups, the study showed the details of fluconazole and nystatin resistance. Fluconazole resistance was detected significantly higher in 86.7% of the cases group compared with only 56.7% of the subjects in the control group (P=0.010). Similarly, nystatin resistance was significantly higher in 76.7% of the cases group, while the control group showed 23.3% drug resistance (P< 0.001). Conclusion: Treating COVID-19 patients with hydroxychloroquine and azithromycin negatively impacted the antimicrobial resistance (AMR) of oral candidiasis. Given the limited efficacy of both treatments, avoiding the broad-spectrum use of both agents in managing COVID-19 patients is advisable.

DOI

10.21608/ejmm.2023.277777

Keywords

COVID-19, Antimicrobial resistance, Azithromycin, hydroxychloroquine

Authors

First Name

Mahmoud

Last Name

El-Ansary

MiddleName

-

Affiliation

Department of Immunology and Medical Microbiology, Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt

Email

melansary2022@gmail.com

City

-

Orcid

0000-0003-2458-1930

First Name

Amira

Last Name

El-Ansary

MiddleName

R.

Affiliation

Department of internal medicine, Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt.

Email

amira.elansary@must.edu.eg

City

-

Orcid

-

Volume

32

Article Issue

1

Related Issue

38243

Issue Date

2023-01-01

Receive Date

2023-01-01

Publish Date

2023-01-01

Page Start

55

Page End

60

Print ISSN

1110-2179

Online ISSN

2537-0979

Article File

EJMM_Volume 32_Issue 1_Pages 55-60.pdf

PDF . 261.7kB

Link

https://ejmm.journals.ekb.eg/article_277777.html

Detail API

https://ejmm.journals.ekb.eg/service?article_code=277777

Order

277,777

Type

New and original researches in the field of Microbiology.

Type Code

2,038

Publication Type

Journal

Publication Title

Egyptian Journal of Medical Microbiology

Publication Link

https://ejmm.journals.ekb.eg/

MainTitle

Resistance of Oral Candida albicans Infection to Fluconazole and Nystatin among Healthy Persons after Treatment with Azithromycin and Hydroxychloroquine to Treat Suspected SARS-C

Details

Type

Article

Created At

23 Jan 2023